Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 12, 2017. The document serves as a transaction notification reporting acquisitions of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| June 9, 2017 | Ordinary Shares (25p each) | £17.0095 | 128 Shares | London Stock Exchange (XLON) |
Note: The total volume of 128 shares is the aggregate of 10 separate transactions by individual executives, ranging from 14 to 16 shares each.
Material Changes
No material changes to the company's financial position, operations, or strategy are reported in this filing. The document solely records routine equity compensation acquisitions by senior management.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of insider trading activity compliant with the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares under the Company's Share Reward Plan, not open market sales.
- Participants: Transactions involved 10 senior executives, including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and President of R&D (Dr P J T Vallance).
- Valuation: All shares were acquired at a uniform price of £17.0095 per share.
- Scope: The filing does not contain financial performance data; investors must refer to Form 20-F or quarterly reports for revenue and earnings information.